Even in the era of TKI treatment in CML, blastic transformation can occur with the translocation involving EVI1 locus,41,42 which is crucial because the clinical outcomes of CML plummet from CP (80%) to BC (20%).43,44 Allogeneic HSC transplantation is so far the only potential remedy for high EVI1 cases of CML-BC as well as AML, emphasizing the need for new therapy targeting EVI1.18,21,45,46. This evidence concerns the gene MECOM and chronic myelogenous leukemia, BCR-ABL1 positive.